Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-15 in relapsed/refractory multiple myeloma
NCT06304636Phase 1Terminated
- Sponsor
- Cartesian Therapeutics
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of descartes-15 in multiple myeloma (MM) (3 arms), sponsored by Cartesian Therapeutics. Primary endpoint: Safety of Descartes-15. Started Jun 2024; status: terminated.
02
Drugs
descartes-15
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06304636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304636.